TCRTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:17):

Stats
本日の出来高	27 500.00
平均出来高	89 034.00
時価総額	21.22M
EPS	$0 ( 2024-04-02 )
次の収益日	( $-0.450 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.0230 (1.74%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Groenewald Ferdinand	Buy	0
2024-01-20	Hogue Dale Curtis Jr.	Buy	600 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	150 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	41 667	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	0

INSIDER POWER
96.78
Last 87 transactions
Buy: 16 191 500 \| Sell: 2 243 866

Alaunos Therapeutics, 相関

10 最も正の相関
WISA	0.942
ALZN	0.935
TTCF	0.935
KVSB	0.932
ALLO	0.931
GH	0.927
ADSE	0.926
AGFY	0.925
COMT	0.925
INFI	0.924

10 最も負の相関
IBEX	-0.937
ISIG	-0.92
STAY	-0.914
RNLC	-0.913
CCRC	-0.912
SLGN	-0.91
USLB	-0.904
SEDG	-0.903
XOMAO	-0.903
VLYPO	-0.894

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Alaunos Therapeutics, 相関 - 通貨/商品

0.49
( neutral )

0.79
( moderate )

0.00
( neutral )

0.23
( neutral )

0.21
( neutral )

0.89
( strong )

Alaunos Therapeutics, 財務諸表

Annual	2023
収益:	$5 000.00
総利益:	$-2.31M (-46 200.00 %)
EPS:	$-2.20

FY	2023
収益:	$5 000.00
総利益:	$-2.31M (-46 200.00 %)
EPS:	$-2.20

FY	2022
収益:	$2.92M
総利益:	$163 000 (5.58 %)
EPS:	$-2.60

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Alaunos Therapeutics,

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.